NCT07205159View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

August 3, 2026

Study Completion Date

December 12, 2026

Conditions
Alopecia Areata
Interventions
DRUG

FB102

Route of administration- Intravenous (IV)

DRUG

Placebo

Route of administration- Intravenous (IV)

Trial Locations (6)

2065

St Leonards, Saint Leonards

3141

South Yarra, South Yarra

4151

Coorparoo, Coorparoo

4414

Palmerston North, Palmerston North

8013

Christchurch, Christchurch

0632

Auckland, Auckland

Sponsors
All Listed Sponsors
lead

Forte Biosciences, Inc.

INDUSTRY